Evidence map›Paper›PMID 38978394›Full record

ReviewCancer prevention research (Philadelphia, Pa.)2024

Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives.

Sanghoon Han, Ramireddy Bommireddy, Pauline Kim, Periasamy Selvaraj, Dong M Shin

Abstract readReview
In one paragraph

Review in Cancer prevention research (Philadelphia, Pa.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Therapeutic targeting of COX-2 in head and neck cancer: Mechanistic and clinical perspectives.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sanghoon Han *Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0003-0976-9134
Ramireddy Bommireddy *Winship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0001-7367-3159
Pauline KimWinship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0009-0001-4706-8120
Periasamy SelvarajWinship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0003-3130-0551
Dong M ShinWinship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0002-8245-4174

Funding

Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neckR01CA262123 · NCI · EMORY UNIVERSITY · PI DONG M SHIN, Periasamy Selvaraj · 2023 to 2026
$2.6M
Second Primary Tumor Prevention w/EGFR TKIs & COX-2 inhibitors in H & N CancerR01CA112643 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2006 to 2011
$1.6M
Mechanism of chemopreventive synergism from the combination of EGCG and ErlotinibR03CA159369 · NCI · EMORY UNIVERSITY · PI AMIN, A.R.M. RUHUL · 2012 to 2013
$150k
National Cancer Institute (NCI) R01CA112643National Cancer Institute (NCI) R01CA262123NCI NIH HHS R01 CA112643NCI NIH HHS R01 CA262123NCI NIH HHS R03 CA159369
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a spectrum of heterogeneous malignancies. A variety of genetic, environmental, and lifestyle factors contribute to the development of HNSCC. Carcinogenesis is a multistep process in which cell proliferation-associated oncogenes and cell-cycle regulation-associated tumor suppressor genes are dysregulated, resulting in premalignant lesions. Immune evasion is a critical step in the progression of benign lesions to advanced cancer. This review discusses the advances that have been made in chemoprevention strategies for HNSCC. The rationale for the use of chemopreventive agents to inhibit head and neck cancer development is highlighted by the positive outcomes of several clinical trials. We discuss the potential of some of the commonly studied agents including vitamin A analogs, EGFR inhibitors, COX-2 inhibitors, metabolic modulators, and natural compounds such as green tea, as well as immunotherapy and photodynamic therapy to prevent HNSCC. Our review provides insight into the potential benefits of these agents and the gaps that remain to be addressed. The published results reaffirm the promise of chemoprevention in head and neck cancer and suggest that continued exploration is needed to overcome the limitations. Because the current focus on chemopreventive agents is limited, major efforts in precision oncology approaches and substantial increase in funding will promote research into chemoprevention, which will eventually decrease the incidence of HNSCC.

Indexed as

ChemopreventionHead and Neck NeoplasmsAnimalsAnticarcinogenic AgentsHumansSquamous Cell Carcinoma of Head and NeckAnticarcinogenic Agents

Identifiers

PMID38978394
PMCPMC11844769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.